EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a pan‐tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates

Nikki McArthur iD, Bokyung Kang, Felix G Rivera Moctezuma, Akber T Shaikh, Kathryn Loeffler, Nemil N Bhatt, Madison Kidd, Jennifer M Zupancic, Alec A Desai, Naima Djeddar, Anton Bryksin, Peter M Tessier und 3 weitere

Biotechnology Progress · 2024

DOI: 10.1002/btpr.3463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Progress, 2024. Verfasst von Nikki McArthur und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: tau Proteins, Single-Domain Antibodies. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease and other tauopathies are characterized by the misfolding and aggregation of the tau protein into oligomeric and fibrillar structures. Antibodies against tau play an increasingly important role in studying these neurodegenerative diseases and the generation of tools to diagnose and treat them. The development of antibodies that recognize tau protein aggregates, however, is hindered by complex immunization and antibody selection strategies and limitations to antigen presentation. Here, we have taken a facile approach to identify single‐domain antibodies, or nanobodies, that bind to many forms of tau by screening a synthetic yeast surface display nanobody library against monomeric tau and creating multivalent versions of our lead nanobody, MT3.1, to increase its avidity for tau aggregates. We demonstrate that MT3.1 binds to tau monomer, oligomers, and fibrils, as well as pathogenic tau from a tauopathy mouse model, despite being identified through screens against monomeric tau. Through epitope mapping, we discovered binding epitopes of MT3.1 contain the key motif VQIXXK which drives tau aggregation. We show that our bivalent and tetravalent versions of MT3.1 have greatly improved binding ability to tau oligomers and fibrils compared to monovalent MT3.1. Our results demonstrate the utility of our nanobody screening and multivalent design approach in developing nanobodies that bind amyloidogenic protein aggregates. This approach can be extended to the generation of multivalent nanobodies that target other amyloid proteins and has the potential to advance the research and treatment of neurodegenerative diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsSingle-Domain AntibodiesAnimalsMiceHumansTauopathiesEpitope MappingProtein AggregatesAlzheimer Disease

Stichwörter der Autor:innen

Alzheimer's diseaseaggregateamyloidmultivalencynanobodytauyeast surface display

Substanzen

tau ProteinsSingle-Domain AntibodiesProtein Aggregates

Autor:innen und Institutionen

  • School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
  • George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
  • Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
  • Mitchell Center for Neurodegenerative Disease, University of Texas Medical Branch, Galveston, Texas, USA.
  • Department of Neurology, University of Texas Medical Branch, Galveston, Texas, USA.
  • Department of Chemical Engineering, University of Michigan, North Campus Research Complex, Ann Arbor, Michigan, USA.

ORCID-Profile: Nikki McArthur, Ravi S Kane

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • NIA NIH HHS
  • National Science Foundation
  • National Institutes of Health

Zitieren

APA

McArthur, N., Kang, B., Rivera Moctezuma, F. G., Shaikh, A. T., Loeffler, K., Bhatt, N. N., Kidd, M., Zupancic, J. M., Desai, A. A., Djeddar, N., Bryksin, A., Tessier, P. M., Kayed, R., Wood, L. B., & Kane, R. S. (2024). Development of a pan‐tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates. Biotechnology Progress. https://doi.org/10.1002/btpr.3463

Vancouver

McArthur N, Kang B, Rivera Moctezuma FG, Shaikh AT, Loeffler K, Bhatt NN, et al. Development of a pan‐tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates. Biotechnology Progress. 2024. doi:10.1002/btpr.3463

BibTeX
@article{McArthur2024,
  author = {McArthur, Nikki and Kang, Bokyung and Rivera Moctezuma, Felix G and Shaikh, Akber T and Loeffler, Kathryn and Bhatt, Nemil N and Kidd, Madison and Zupancic, Jennifer M and Desai, Alec A and Djeddar, Naima and Bryksin, Anton and Tessier, Peter M and Kayed, Rakez and Wood, Levi B and Kane, Ravi S},
  title = {Development of a pan‐tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates},
  journal = {Biotechnology Progress},
  year = {2024},
  doi = {10.1002/btpr.3463}
}
Kostenlos starten →